Success Metrics

Clinical Success Rate

60.0%

Based on 6 completed trials

Completion Rate

60%(6/10)

Active Trials

0(0%)

Results Posted

17%(1 trials)

Terminated

4(25%)

Phase Distribution

Ph not_applicable

31%

Ph phase_3

31%

Ph phase_4

Ph phase_2

31%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution16 total trials

Phase 2Efficacy & side effects

5(31.3%)

Phase 3Large-scale testing

5(31.3%)

Phase 4Post-market surveillance

1(6.3%)

N/ANon-phased studies

5(31.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

54.5%

6 of 11 finished

Non-Completion Rate

45.5%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Terminated(5)

Other(5)

Detailed Status

Completed6

unknown5

Terminated4

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 4

Trials by Phase

Phase 25 (31.3%)

Phase 35 (31.3%)

Phase 41 (6.3%)

N/A5 (31.3%)

Trials by Status

unknown531%

withdrawn16%

terminated425%

completed638%

Recent Activity

0 active trials

Showing 5 of 16

terminatedphase_2

Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

NCT00417833

withdrawnphase_3

Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

NCT00417716

terminatedphase_3

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

NCT00599820

terminatedphase_2

Intravitreal Bevacizumab for Diabetic Retinopathy

NCT00600262

terminatedphase_4

Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

NCT04991350

View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials

NCT00417833Phase 2

Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

Terminated

NCT00417716Phase 3

Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

Withdrawn

NCT00599820Phase 3

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Terminated

NCT00600262Phase 2

Intravitreal Bevacizumab for Diabetic Retinopathy

Terminated

NCT04991350Phase 4

Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

Terminated

NCT05712642Phase 3

A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity

Completed

NCT01571232Phase 2

Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

Completed

NCT01976923Phase 3

Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy

Completed

NCT03609307Phase 2

Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial

Unknown

NCT02663141Phase 2

Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema

Completed

NCT00997191Phase 3

Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)

Completed

NCT01707745Not Applicable

Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

Unknown

NCT01626339Not Applicable

Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

Unknown

NCT01219205Not Applicable

Major and Macular Branched Retinal Venous Occlusion